Open Beta
MetriLume

US marketsIMNM

SEC-sourced researchBeta

IMNM

Immunome Inc.

Company comparison ↗

Data passport

CIK
0001472012
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 9,041,000.0000 USD; December 2025: 6,941,000.0000 USD9M USD0 USD0December 2024December 2025
IMNM · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20249,041,000.0000Mar 3, 2026
December 20256,941,000.0000Mar 3, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20256,941,000.0000-212,394,000.0000-190,919,000.0000683,188,000.000048,845,000.0000Mar 3, 2026
December 20249,041,000.0000-292,963,000.0000-110,794,000.0000240,241,000.000059,076,000.0000Mar 3, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$6.94MDecember 2025Mar 3, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$9.04MDecember 2024Mar 3, 202610-K
Net incomeNetIncomeLoss-$212.39MDecember 2025Mar 3, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$190.92MDecember 2025Mar 3, 202610-K
Total assetsAssets$683.19MDecember 2025Mar 3, 202610-K
Total liabilitiesLiabilities$48.85MDecember 2025Mar 3, 202610-K

New filings

Explore methodology ↗